Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

Jennifer Woyach, MD, Ying Huang, MS, MA, Kerry Rogers, Seema A. Bhat, MD, Michael R. Grever, MD, Arletta Lozanski, Tzyy-Jye Doong, James S. Blachly, MD, Gerard Lozanski, MD, Dan Jones, MD PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 504.

https://doi.org/10.1182/blood-2019-127674

Published: 2019

Journal Articles

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Kerry A Rogers, MD, Lai Wei, PhD, Seema A. Bhat, MD, Dan Jones, MD PhD, Erlene K. Seymour, MD, Deborah M. Stephens, DO, J Christine Ye, MDMSc, John C. Byrd, MD, Jennifer Woyach, MD

Blood (2019) 134 (Supplement_1): 3049.

https://doi.org/10.1182/blood-2019-125360

Published: 2019

Journal Articles

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Blood (2019) 134 (Supplement_1): 2145.

https://doi.org/10.1182/blood-2019-131253

Published: 2019

Journal Articles

Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events

Dan Jones, MD PhD, Huolin Tu, PhD, Jennifer A. Woyach, MD, Kerry A. Rogers, MD, Xiaokang Pan, PhD, Susan Long, Brianna Sisson, Sean Caruthers, Peng Ru, PhD, Nyla A. Heerema, PhD, Gerard Lozanski, MD, Lynne V. Abruzzo, MD PhD, Weiqiang Zhao, MD PhD, John C. Byrd, MD

Blood (2018) 132 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2018-99-116293

Published: 2018

Journal Articles

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Blood (2018) 132 (Supplement 1): 2668.

https://doi.org/10.1182/blood-2018-99-114318

Published: 2018

Journal Articles

Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study

Blood (2017) 130 (Supplement 1): 467.

https://doi.org/10.1182/blood.V130.Suppl_1.467.467

Published: 2017

Journal Articles

Assessment of Mutation Status in a Large Series of Patients with Cytopenias with Normal Karyotypes and without Increased Blasts

Lobin A Lee, MS, Yongbao Wang, PhD, Russell Maiese, MD, Kevin J Arvai, Qiulu Pan, MD, Kumudini Mehta, MD, Sean M Caruthers, Steven L Gersen, PhD, Shere Billouin-Frazier, MS, Frederick Karl Racke, MD PhD, Dan Jones, MD PhD

Blood (2014) 124 (21): 4606.

https://doi.org/10.1182/blood.V124.21.4606.4606

Published: 2014

Journal Articles

In-Frame Exon 9 CALR Deletions Co-Occur with Other Alterations in the JAK-STAT Pathway in Myeloproliferative Neoplasms

Yongbao Wang, PhD, Albert K Ho, MD PhD, Qiulu Pan, MD, Frederick Karl Racke, MD PhD, Dan Jones, MD PhD

Blood (2014) 124 (21): 4588.

https://doi.org/10.1182/blood.V124.21.4588.4588

Published: 2014

Journal Articles

Molecular Monitoring of Acute Myeloid Leukemia: Patterns at Presentation and Post-Therapy

Dan Jones, MD PhD, Albert K Ho, MD PhD, Shere Billouin-Frazier, MS, Yongbao Wang, PhD

Blood (2014) 124 (21): 2366.

https://doi.org/10.1182/blood.V124.21.2366.2366

Published: 2014

Journal Articles

Impaired Precursor B-Cell Maturation/Production In The Bone Marrow: Association With Molecular and Immunophenotypic Markers Of Myeloid Dysplasia In Suspected Low-Grade MDS

Charles Repetti, PhD, Hsueh-Hua Chen, BS, MT, SH, Yongbao Wang, PhD, Vanessa A Jones, MS, MT, Albert K Ho, MD, PhD, Qiulu Pan, MD, Ila Bansal, MD, Dan Jones, MD, PhD

Blood (2013) 122 (21): 4943.

https://doi.org/10.1182/blood.V122.21.4943.4943

Published: 2013

Journal Articles

Comprehensive Workup of Myelodysplastic Syndromes: Comparing Targeted DNA Sequencing, Oligo/SNP Microarray and Higher Dimensional Flow Cytometry.

Marilyn L Slovak, PhD, Ya-Hsuan Hsu, MS, Hseuh-Hua Chen, BS, MT, SH, Yongbao Wang, PhD, Philip N Mowrey, PhD, Charles Repetti, PhD, Albert K Ho, MD, PhD, Qiulu Pan, MD, Ila Bansal, MD, Dan Jones, MD, PhD

Blood (2012) 120 (21): 2519.

https://doi.org/10.1182/blood.V120.21.2519.2519

Published: 2012

Journal Articles

Microarray-Based Genomic Profiling Facilitates Genetic Subgrouping and Detects Critical Submicroscopic Aberrations Associated with Prognosis in Pediatric Acute Lymphoblastic Leukemia (ALL)

Marilyn L Slovak, PhD, Ya-Hsuan Hsu, MS, Jennifer A Otani-Rosa, BS, Jennifer A Jahn, BS, Zunyan Dai, PhD, Marc Sanidad, BS, Philip N Mowrey, PhD, Dan Jones, MD, PhD

Blood (2012) 120 (21): 1444.

https://doi.org/10.1182/blood.V120.21.1444.1444

Published: 2012

Journal Articles

Myeloid Lineage-Associated Mutations Are Detected in Blastic Plasmacytoid Dendritic Cell Neoplasm

Yongbao Wang, PhD, Justin Windham, MS, Shere Billouin-Frazier, MS, Dan Jones, MD, PhD

Blood (2012) 120 (21): 5123.

https://doi.org/10.1182/blood.V120.21.5123.5123

Published: 2012

Journal Articles

Characteristics and Outcome of Patients (pts) with V299L BCR-ABL Kinase Domain (KD) Mutation After Therapy with Tyrosine Kinase Inhibitors (TKIs).

Elias Jabbour, MD, Hagop M. Kantarjian, MD, Dan Jones, MD, PhD, Yin Cameron, MD, PhD, Elizabeth Burton, Jorge Cortes, MD

Blood (2010) 116 (21): 3428.

https://doi.org/10.1182/blood.V116.21.3428.3428

Published: 2010

Journal Articles

Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Farhad Ravandi, MD, Deborah A Thomas, MD, Susan O'Brien, MD, Stefan Faderl, MD, Jeffrey Jorgensen, MD, PhD, Rajyalakshmi Luthra, PhD, Dan Jones, MD, PhD, Rebecca Garris, BA, Jorge E. Cortes, MD, Hagop Kantarjian, MD

Blood (2010) 116 (21): 2127.

https://doi.org/10.1182/blood.V116.21.2127.2127

Published: 2010

Journal Articles

Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML).

Aref Al-Kali, MD, Dan Jones, MD, PhD, Jorge Cortes, MD, Stefan Faderl, MD, Xue Ao, Guillermo Garcia-Manero, MD, Gautam Borthakur, MD, Marina Konopleva, MD, PhD, Mark Brandt, Michael Andreeff, MD, PhD, Hagop Kantarjian, MD, Farhad Ravandi, MD

Blood (2009) 114 (22): 2079.

https://doi.org/10.1182/blood.V114.22.2079.2079

Published: 2009

Journal Articles

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Jorge Cortes, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Elias Jabbour, MD, Charles Koller, MD, Samuel Dara, Rebecca Garris, Partow Kebriaei, MD, Gautam Borthakur, MD, Alessandra Ferrajoli, MD., Susan O'Brien

Blood (2009) 114 (22): 2043.

https://doi.org/10.1182/blood.V114.22.2043.2043

Published: 2009

Journal Articles

Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Gautam Borthakur, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, PhD, Dan Jones, MD, PhD, Varsha Gandhi, PhD, Zeev Estrov, MD, Susan O'Brien, M.D., Farhad Ravandi, MD, Joyce Bass, RN, Mark Brandt, Hagop Kantarjian, MD

Blood (2009) 114 (22): 2056.

https://doi.org/10.1182/blood.V114.22.2056.2056

Published: 2009

Journal Articles

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Jorge Cortes-Franco, MD, H. Jean Khoury, MD, FACP, Franck Emmanuel Nicolini, MD, PhD, Selim Corm, Jeffrey H. Lipton, MD,PhD, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, Eric Humphriss, Hagop Kantarjian, MD

Blood (2009) 114 (22): 644.

https://doi.org/10.1182/blood.V114.22.644.644

Published: 2009

Journal Articles

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

Jorge Cortes-Franco, MD, Digumarti Raghunadharao, MD, Purvish Parikh, MD, Meir Wetzler, MD, Jeffrey H. Lipton, Dan Jones, MD, PhD, Andreas Hochhaus, MD, Hagop M. Kantarjian, MD, Adam R Craig, MD, PhD, Annie-Claude Benichou, Eric Humphriss, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 861.

https://doi.org/10.1182/blood.V114.22.861.861

Published: 2009

NARROW

Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations

A Multicenter Study of Ibrutinib Resistance Development and Intervention with Venetoclax in Patients with Chronic Lymphocytic Leukemia

Newly Diagnosed AML Patient Samples Demonstrate High Degree of Concordance in Identification of Pathogenic Mutations By Next Generation Sequencing (NGS) Performed at Enrolling Institutions Compared to Central Laboratory Results in the Beat AML Master Trial

Mutations in the Ras Pathway in Pre-Treatment Chronic Lymphocytic Leukemia Are Associated with VH1-69: Linking B-Cell Receptor Stereotypy to Downstream Signaling Events

Ratify (Alliance 10603): Prognostic Impact of FLT3 tyrosine Kinase Domain (TKD) and NPM1 Mutation Status in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Treated with Midostaurin or Placebo Plus Standard Chemotherapy

Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study

Assessment of Mutation Status in a Large Series of Patients with Cytopenias with Normal Karyotypes and without Increased Blasts

In-Frame Exon 9 CALR Deletions Co-Occur with Other Alterations in the JAK-STAT Pathway in Myeloproliferative Neoplasms

Molecular Monitoring of Acute Myeloid Leukemia: Patterns at Presentation and Post-Therapy

Impaired Precursor B-Cell Maturation/Production In The Bone Marrow: Association With Molecular and Immunophenotypic Markers Of Myeloid Dysplasia In Suspected Low-Grade MDS

Comprehensive Workup of Myelodysplastic Syndromes: Comparing Targeted DNA Sequencing, Oligo/SNP Microarray and Higher Dimensional Flow Cytometry.

Microarray-Based Genomic Profiling Facilitates Genetic Subgrouping and Detects Critical Submicroscopic Aberrations Associated with Prognosis in Pediatric Acute Lymphoblastic Leukemia (ALL)

Myeloid Lineage-Associated Mutations Are Detected in Blastic Plasmacytoid Dendritic Cell Neoplasm

Characteristics and Outcome of Patients (pts) with V299L BCR-ABL Kinase Domain (KD) Mutation After Therapy with Tyrosine Kinase Inhibitors (TKIs).

Dynamics of Minimal Residual Leukemia After Combinations of the HyperCVAD Regimen with Imatinib or Dasatinib In Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia

Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML).

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin.

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only